Deep Clever Pharma Raises Almost US$50 Million in Sequence D Funding to Reinvent the Full Scientific Trial Workflow with AI

On December 11, 2025, Deep Clever Pharma (DIP), a worldwide chief in AI-driven drug improvement, introduced that it has raised practically US$50 million in Sequence D financing. The spherical was led by CDH Baifu, with continued participation from present buyers New Ding Capital and Sequoia China. Index Capital served because the unique monetary advisor. The brand new funds will probably be used to additional develop DIP’s “multi-agent collaborative community” and develop its international supply infrastructure.

Based in 2017, DIP has, over the previous three years, advanced from validating remoted AI applied sciences to constructing an AI-native scientific analysis platform, positioning itself as a full-process scientific trial resolution supplier. Its core know-how, the mult i-agent collaboration system, is constructed on a “cognitive atom idea” that breaks scientific research into tens of 1000’s of atomic duties, every accomplished by specialised AI brokers. These brokers work together by synapse-like community connections, enabling a stage of area experience that surpasses general-purpose massive fashions.

On the enterprise entrance, DIP is transferring past the business’s typical hourly billing mannequin towards a milestone-based worth pricing strategy. By way of information safety, the corporate adheres to strict rules of “information stays on-site” and “fashions don’t retain reminiscence.” All tasks run inside unbiased bodily sandboxes, that are destroyed upon undertaking completion.

To this point, DIP has served over 1,000 pharmaceutical corporations, delivering greater than 40,000 tasks, together with supporting Japan’s Immunorock in acquiring one-time PMDA approval. Founder Li Xing says the corporate goals to construct a “pharmaceutical R&D working system” that frees scientists to concentrate on true innovation.